GO:0008028 monocarboxylic acid transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008028 describes the molecular function of moving monocarboxylic acids (organic acids with one COOH group, e.g., lactate, pyruvate, ketone bodies, thyroid hormones) across a membrane.
• The SLC16 gene family (MCT1–MCT14) encodes the best-characterized proton-coupled monocarboxylic acid transporters, with MCT1 (SLC16A1) and MCT4 (SLC16A3) central to lactate shuttling.
• MCT8 (SLC16A2) and MCT10 (SLC16A10) transport thyroid hormones and are linked to Allan-Herndon-Dudley syndrome and thyroid hormone signaling defects.
• Transport can be proton-coupled, sodium-coupled, or facilitated diffusion, and some transporters exhibit intrinsic asymmetry in substrate handling.
• CD147 (basigin) is an essential ancillary protein for several MCTs, and its loss impairs transporter trafficking and function.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are key tools for dissecting transporter specificity, regulation, and disease relevance.
Description
Monocarboxylic acid transmembrane transporter activity (GO:0008028) is a molecular function that enables the transfer of monocarboxylic acids from one side of a membrane to the other. Monocarboxylic acids are organic acids containing a single carboxyl group, and this class includes metabolites such as lactate, pyruvate, ketone bodies, and short-chain fatty acids, as well as signaling molecules like thyroid hormones and prostaglandins. Because these molecules are charged at physiological pH, their movement across lipid bilayers requires dedicated transport proteins. The SLC16 family of monocarboxylate transporters (MCTs) represents the archetypal implementation of this GO term, with MCT1–MCT14 displaying distinct substrate preferences, tissue distributions, and coupling mechanisms. Researchers study GO:0008028 to understand metabolic flux, endocrine signaling, and the pathophysiology of diseases ranging from cancer to thyroid hormone transport disorders. The activity is not limited to a single protein family; other solute carriers and channels can also exhibit monocarboxylic acid transport, but the SLC16 family remains the most extensively characterized.
monocarboxylic acid transmembrane transporter activity At A Glance
| GO ID | GO:0008028 |
|---|---|
| GO term | monocarboxylic acid transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | monocarboxylate carrier; prostaglandin/thromboxane transporter activity |
| Major function | Transfer of monocarboxylic acids across a membrane |
| Representative family | SLC16 (MCT1–MCT14) |
| Coupling modes | Proton-coupled, sodium-coupled, or facilitated diffusion |
| Key substrates | Lactate, pyruvate, ketone bodies, thyroid hormones, short-chain fatty acids |
| Ancillary proteins | CD147 (basigin), embigin, and others |
What Is GO:0008028?
In simple terms, GO:0008028 is the job of carrying a monocarboxylic acid across a cell membrane. The official definition states: Enables the transfer of monocarboxylic acids from one side of a membrane to the other. A monocarboxylic acid is an organic acid with one COOH group. This function is typically performed by integral membrane proteins that facilitate or actively pump substrates such as lactate, pyruvate, ketone bodies, and thyroid hormones. The term is a molecular_function in the Gene Ontology and includes synonyms such as monocarboxylate carrier and prostaglandin/thromboxane transporter activity.
Why Is monocarboxylic acid transmembrane transporter activity Important in Cell Biology?
Monocarboxylic acid transmembrane transporter activity is fundamental to cellular metabolism, pH regulation, and inter-organ communication. Lactate transport via MCT1 and MCT4 supports the lactate shuttle between glycolytic and oxidative tissues, a process critical for muscle, brain, and tumor metabolism. Thyroid hormone transport by MCT8 and MCT10 is essential for neurodevelopment, and mutations in SLC16A2 cause Allan-Herndon-Dudley syndrome, a severe X-linked intellectual disability disorder. In cancer, MCT1 and MCT4 are often upregulated to handle the high glycolytic flux, and CD147 is a well-known tumor-associated protein that promotes malignancy. Thus, GO:0008028 is a focal point for understanding metabolic diseases, endocrine disorders, and cancer biology.
• Enables lactate shuttling between glycolytic and oxidative cells, a key feature of the Warburg effect in cancer.
• Supports ketone body transport, which is vital during fasting and in the brain.
• Mediates thyroid hormone uptake, with defects causing Allan-Herndon-Dudley syndrome.
• Regulates intracellular pH through proton-coupled monocarboxylate efflux.
• Contributes to drug transport and pharmacokinetics for monocarboxylic acid drugs.
• Involved in prostaglandin/thromboxane transport, linking to inflammation and vascular biology.
• CD147 association influences tumor progression, metastasis, and immune responses.
• Provides targets for inhibitors such as silychristin, a potent MCT8 inhibitor.
• Essential for metabolic reprogramming in immune cells and stem cells.
• Offers biomarkers and therapeutic targets in metabolic and endocrine disorders.
What Happens During monocarboxylic acid transmembrane transporter activity?
Substrate recognition and binding
In simple terms: The transporter first grabs the monocarboxylic acid it will carry.
Monocarboxylate transporters recognize substrates via specific residues in their transmembrane domains. For MCT1, key residues such as Arg306 and His302 are involved in substrate binding and proton coupling. The substrate specificity varies: MCT1 transports lactate, pyruvate, and ketone bodies, while MCT8 preferentially transports thyroid hormones. Structural and mutational studies have revealed that the transporter undergoes conformational changes to accommodate the substrate.
Conformational cycling and translocation
In simple terms: The transporter changes shape to move the acid across the membrane.
After binding, the transporter cycles between outward-facing and inward-facing conformations, a process known as the alternating access mechanism. For proton-coupled MCTs, the proton and monocarboxylate are co-transported, with the proton gradient driving the process. Recent studies have highlighted intrinsic asymmetry in weak acid transporters, where the rates of substrate influx and efflux differ, influencing net transport direction.
Release and reset
In simple terms: The acid is released on the other side, and the transporter resets.
Upon reaching the opposite side of the membrane, the substrate is released into the cytoplasm or extracellular space, and the transporter returns to its initial conformation. This cycle is essential for maintaining metabolic gradients and pH homeostasis. The direction of net transport depends on substrate and proton gradients, as well as membrane potential.
Ancillary protein interactions
In simple terms: Helper proteins like CD147 are needed for the transporter to work properly.
Many MCTs require ancillary proteins for proper folding, trafficking, and activity. CD147 (basigin) is a widely expressed ancillary protein that associates with MCT1, MCT3, and MCT4, and is critical for their cell surface expression. Loss of CD147 impairs lactate transport and affects tumor cell metabolism. Other ancillary proteins include embigin for MCT2 and gp70 for MCT4.
Key Genes Involved in GO:0008028 monocarboxylic acid transmembrane transporter activity
The following genes encode proteins that exhibit monocarboxylic acid transmembrane transporter activity or are essential ancillary components, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC16A1 (MCT1) | Proton-coupled transporter for lactate, pyruvate, ketone bodies | Widely expressed; target in cancer metabolism and lactate shuttle |
| SLC16A3 (MCT4) | Proton-coupled lactate exporter | Highly expressed in glycolytic tissues and tumors; marker of poor prognosis |
| SLC16A2 (MCT8) | Thyroid hormone transporter | Mutations cause Allan-Herndon-Dudley syndrome; key for brain thyroid hormone uptake |
| SLC16A7 (MCT2) | High-affinity lactate/pyruvate transporter | Neuronal lactate uptake; involved in memory and neuroprotection |
| SLC16A8 (MCT3) | Lactate transporter in retinal pigment epithelium | Role in retinal metabolism and visual cycle |
| SLC16A10 (MCT10) | Aromatic amino acid and thyroid hormone transporter | Thyroid hormone transport; potential modifier of MCT8 deficiency |
| SLC16A11 | Monocarboxylic acid transporter | Associated with type 2 diabetes risk in some populations |
| SLC16A13 | Monocarboxylic acid transporter | Less characterized; potential metabolic roles |
| BSG (CD147) | Ancillary protein for MCT1, MCT3, MCT4 | Essential for trafficking; promotes tumor invasion and metastasis |
| EMB (Embigin) | Ancillary protein for MCT2 | Required for MCT2 function in neurons |
| SLC5A8 | Sodium-coupled monocarboxylate transporter | Tumor suppressor; transports butyrate and pyruvate |
| SLC5A12 | Sodium-coupled monocarboxylate transporter | Expressed in kidney and immune cells; lactate transport |
| SLC22A1 (OCT1) | Organic cation transporter; also transports monocarboxylates | Drug transport and metabolism |
| SLC22A7 (OAT2) | Organic anion transporter; monocarboxylate transport | Hepatic and renal transport |
| SLC25A10 | Mitochondrial dicarboxylate/monocarboxylate carrier | Mitochondrial metabolism |
| SLC27A1 (FATP1) | Fatty acid transport protein; monocarboxylic acid transport | Lipid metabolism and insulin resistance |
| SLC27A4 (FATP4) | Fatty acid transport protein | Skin barrier and lipid absorption |
| ABCC1 (MRP1) | ATP-binding cassette transporter; transports monocarboxylates | Multidrug resistance and inflammation |
How Is monocarboxylic acid transmembrane transporter activity Regulated?
Monocarboxylic acid transmembrane transporter activity is regulated at multiple levels. Transcriptional regulation by hypoxia-inducible factor 1 (HIF-1) increases MCT4 expression under low oxygen, supporting glycolytic metabolism. Post-translational modifications, such as phosphorylation and ubiquitination, affect transporter stability and trafficking. The interaction with ancillary proteins like CD147 is crucial for proper localization and function. Additionally, substrate availability and proton gradients dynamically influence transport rates. In thyroid hormone transport, MCT8 activity can be modulated by inhibitors such as silychristin, and its expression is regulated during brain development.
monocarboxylic acid transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC16A2 (MCT8) | Allan-Herndon-Dudley syndrome; brain thyroid hormone deficiency | Knockout mouse, patient iPSC-derived neurons, knock-in of patient mutations |
| SLC16A1 (MCT1) | Cancer metabolism; lactate shuttle | Cancer cell line knockout, xenograft models, overexpression |
| SLC16A3 (MCT4) | Tumor glycolysis and metastasis | Knockout in cancer cells, organoids, CRISPR screens |
| BSG (CD147) | Cancer progression, inflammation, malaria | Knockout mice, antibody blockade, knock-in tagging |
| SLC16A11 | Type 2 diabetes risk | Knockout hepatocytes, knock-in variant models |
Allan-Herndon-Dudley syndrome and thyroid hormone transport defects
Mutations in SLC16A2 (MCT8) cause Allan-Herndon-Dudley syndrome, an X-linked disorder characterized by severe intellectual disability, hypotonia, and altered thyroid hormone levels. MCT8 is critical for thyroid hormone uptake into neurons, and its loss leads to brain hypothyroidism despite normal serum hormone levels. Inactivation of MCT8 and OATP1C1 in mouse brain endothelial cells causes region-specific alterations in central thyroid hormone signaling, highlighting the importance of transport across the blood-brain barrier. These findings underscore the role of GO:0008028 in neurodevelopment and endocrine disorders.
Cancer metabolism and CD147
Many cancers upregulate MCT1 and MCT4 to handle high glycolytic flux, exporting lactate to maintain intracellular pH and support tumor growth. CD147 (basigin), an ancillary protein for these transporters, is overexpressed in many tumors and promotes invasion, metastasis, and angiogenesis. Targeting MCT1/MCT4 or CD147 has been proposed as a therapeutic strategy, and inhibitors are under investigation. Thus, GO:0008028 is directly linked to cancer hallmarks and metabolic reprogramming.
Metabolic disorders and diabetes
Genetic variants in SLC16A11 are associated with type 2 diabetes in some populations, and the transporter is thought to influence hepatic lipid metabolism. Monocarboxylate transport also affects insulin secretion and glucose homeostasis, as lactate and pyruvate are important signaling molecules in pancreatic beta cells. Understanding GO:0008028 in these contexts may reveal new therapeutic targets for metabolic diseases.
From monocarboxylic acid transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MCT1 affect lactate transport and tumor growth? | SLC16A1 knockout cancer cell lines and xenografts |
| What is the effect of MCT8 patient mutations on thyroid hormone transport? | Point-mutation knock-in in cell lines or patient iPSC-derived neurons |
| Can CD147 be tagged to track MCT1 localization? | Knock-in of fluorescent or epitope tags at the BSG locus |
| Does overexpression of MCT4 enhance glycolytic capacity? | Doxycycline-inducible overexpression in cancer cells |
| What is the role of MCT8 in brain development? | Conditional knockout in mouse brain endothelial cells |
| Can CRISPR screens identify modifiers of monocarboxylate transport? | Genome-wide CRISPR knockout library screening in transport assays |
How to Study the monocarboxylic acid transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uptake assay | Transport rate of monocarboxylic acids | Characterizing MCT1/MCT4 activity in cancer cells |
| Fluorescent substrate assay | Real-time transport and inhibition | High-throughput screening for inhibitors |
| CRISPR knockout | Loss-of-function effects on transport | Validating gene function in cell lines |
| CRISPR knock-in | Tagged or mutant transporter expression | Localization and trafficking studies |
| RNA-seq | Transcriptional changes in transporters | Hypoxia or metabolic stress responses |
| Proteomics | Protein interactions and abundance | Identifying ancillary proteins like CD147 |
| Cryo-EM | Three-dimensional structure | Mechanistic understanding of transport |
| PET imaging | In vivo transport activity | Brain thyroid hormone uptake studies |
Transport assays
Radiolabeled or fluorescent monocarboxylic acid uptake assays are used to measure transport activity directly. For example, 14C-lactate or fluorescent thyroid hormone analogs can be used in cell lines expressing specific transporters. These assays are often performed in the presence or absence of inhibitors like silychristin to determine specificity.
Genetic manipulation and CRISPR screens
CRISPR-Cas9 knockout, point mutation, and knock-in models allow precise interrogation of transporter function. Genome-wide CRISPR screens can identify genes that modulate monocarboxylate transport or sensitivity to inhibitors. These approaches are complemented by RNA-seq and proteomics to assess expression changes.
Structural and biophysical methods
Cryo-EM and X-ray crystallography have provided insights into the structure of MCTs and related transporters, revealing the alternating access mechanism and substrate binding sites. Molecular dynamics simulations and electrophysiology can further probe conformational changes and electrogenicity.
In vivo models and imaging
Mouse models with conditional knockouts or knock-ins of SLC16 genes are used to study tissue-specific roles. Imaging techniques such as PET with radiolabeled substrates can monitor transport in living animals. These models are essential for understanding systemic metabolism and endocrine effects.
How CRISPR Can Be Used to Study GO:0008028 monocarboxylic acid transmembrane transporter activity
Knockout
CRISPR knockout of SLC16 genes or BSG (CD147) is used to abolish transporter activity and study downstream metabolic and signaling consequences. For example, SLC16A1 knockout reduces lactate uptake and affects tumor growth in xenograft models. Knockout of SLC16A2 in mice recapitulates features of Allan-Herndon-Dudley syndrome.
Point Mutation
Point mutations identified in patients, such as those in SLC16A2 causing MCT8 deficiency, can be introduced into cell lines or animal models using CRISPR base editing or homology-directed repair. These models help determine whether a specific mutation is causal and reveal structure-function relationships.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags into endogenous SLC16 or BSG loci allows real-time tracking of transporter localization and dynamics. Knock-in of reporter genes can also be used to monitor transporter expression in vivo.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of SLC16 genes can be used to study gain-of-function effects, such as enhanced lactate transport or thyroid hormone uptake. Overexpression models are valuable for testing whether increased transporter activity is sufficient to drive metabolic or disease phenotypes.
How EDITGENE Supports monocarboxylic acid transmembrane transporter activity Research
Researchers studying monocarboxylic acid transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, metabolism, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for monocarboxylic acid transmembrane transporter activity research.
Frequently Asked Questions About monocarboxylic acid transmembrane transporter activity
What is GO:0008028?
GO:0008028 is the Gene Ontology molecular function term for monocarboxylic acid transmembrane transporter activity, which enables the transfer of monocarboxylic acids across a membrane.
What genes are involved in monocarboxylic acid transmembrane transporter activity?
Key genes include SLC16A1 (MCT1), SLC16A3 (MCT4), SLC16A2 (MCT8), SLC16A7 (MCT2), SLC16A10 (MCT10), and the ancillary protein BSG (CD147).
What diseases are linked to monocarboxylic acid transporters?
They are linked to Allan-Herndon-Dudley syndrome (MCT8 mutations), cancer metabolism (MCT1/MCT4/CD147), and type 2 diabetes (SLC16A11).
How is monocarboxylic acid transport regulated?
It is regulated by hypoxia (HIF-1), ancillary proteins like CD147, post-translational modifications, and substrate gradients.
What is the role of MCT8 in the brain?
MCT8 transports thyroid hormones into neurons and across the blood-brain barrier; its loss causes brain hypothyroidism and neurodevelopmental defects.
Can CRISPR be used to study monocarboxylic acid transporters?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect transporter function and disease mechanisms.
What are the substrates of monocarboxylic acid transporters?
Substrates include lactate, pyruvate, ketone bodies, thyroid hormones, short-chain fatty acids, and prostaglandins.
What is CD147 and how does it relate to MCTs?
CD147 (basigin) is an ancillary protein required for the proper trafficking and function of several MCTs, including MCT1 and MCT4.
Are there inhibitors of monocarboxylic acid transporters?
Yes, silychristin is a potent inhibitor of MCT8, and other inhibitors are being developed for cancer and metabolic studies.
How can I model MCT8 deficiency in the lab?
Patient iPSC-derived neurons, knock-in mice with patient mutations, and knockout cell lines are common models for MCT8 deficiency.
Conclusion
Monocarboxylic acid transmembrane transporter activity (GO:0008028) is a fundamental molecular function that governs the movement of key metabolites and hormones across cellular membranes. The SLC16 family and its ancillary proteins are central to this activity, with profound implications for metabolism, neurodevelopment, and cancer. Continued research using advanced CRISPR models and transport assays will further illuminate the mechanistic details and therapeutic potential of these transporters.
References
- 1. Halestrap AP. 2013. The SLC16 gene family - structure, role and regulation in health and disease.. Mol Aspects Med 34(2-3):337-49 PMID: 23506875
- 2. Halestrap AP. 2013. Monocarboxylic acid transport.. Compr Physiol 3(4):1611-43 PMID: 24265240
- 3. Becker PC et al.. 2024. Identification of Human TRIAC Transmembrane Transporters.. Thyroid 34(7):920-930 PMID: 38801167
- 4. Johannes J et al.. 2016. Silychristin, a Flavonolignan Derived From the Milk Thistle, Is a Potent Inhibitor of the Thyroid Hormone Transporter MCT8.. Endocrinology 157(4):1694-701 PMID: 26910310
- 5. Nyalali AMK et al.. 2023. CD147: an integral and potential molecule to abrogate hallmarks of cancer.. Front Oncol 13:1238051 PMID: 38023152
- 6. Jaeger E et al.. 2026. Intrinsic Asymmetry in Weak Acid Transmembrane Transporters.. Biomolecules 16(1) PMID: 41594631
- 7. Alevyzaki A et al.. 2025. Inactivation of Thyroid Hormone Transporters Mct8/Oatp1c1 in Mouse Brain Endothelial Cells Causes Region-Specific Alterations in Central Thyroid Hormone Signaling.. Thyroid 35(7):816-827 PMID: 40622283
- 8. Groeneweg S et al.. 2017. Disorder of thyroid hormone transport into the tissues.. Best Pract Res Clin Endocrinol Metab 31(2):241-253 PMID: 28648511
